Complement-binding anti-HLA antibodies and kidney-allograft survival

New England Journal of Medicine

Volumn 369, Issue 13, 2013, Pages 1215-1226

  Loupy, Alexandre ^a,b   Lefaucheur, Carmen ^a,b   Vernerey, Dewi ^b   Prugger, Christof ^b   Van Huyen, Jean Paul Duong ^a,b,c   Mooney, Nuala ^d   Suberbielle, Caroline ^a   Frémeaux Bacchi, Véronique ^a,c   Méjean, Arnaud ^c   Desgrandchamps, François ^a   Anglicheau, Dany ^a   Nochy, Dominique ^c   Charron, Dominique ^a   Empana, Jean Philippe ^b   Delahousse, Michel ^a,e   Legendre, Christophe ^a   Glotz, Denis ^a,d   Hill, Gary S ^c   Zeevi, Adriana ^f   Jouven, Xavier ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d INSERM   (France)

^e FOCH HOSPITAL   (France)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4D; HLA ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; COHORT ANALYSIS; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; FEMALE; FRANCE; GRAFT FAILURE; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BINDING; VASCULITIS;

EID: 84884505267     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1302506     Document Type: Article

References (40)

1. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011;378:1428-37.
2. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010;90:68-74.
3. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonad-herence. Am J Transplant 2012;12:388-99.
4. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 data report. Am J Transplant 2012;12:Suppl 1:1-156.
5. Rapport 2011 de l'activité de prélèvement et de greffe de l'Agence de la Biomédecine (http://www.agence-biomedecine.fr/ Rapport-annuel-2011).
6. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004;4:438-43. (Pubitemid 38282302)
7. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005;16:2804-12.
8. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009;87:1505-13.
9. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010;21:1398-406.
10. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med 2010;363:1451-62.
11. Racusen LC, Haas M. Antibody-mediated rejection in renal allografts: lessons from pathology. Clin J Am Soc Nephrol 2006;1:415-20.
12. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007;18:1046-56. (Pubitemid 46536891)
13. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969;280:735-9.
14. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991;86:464-70.
15. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999;10:2208-14. (Pubitemid 29453499)
16. Böhmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloanti-body-dependent graft injury. J Am Soc Nephrol 2002;13:1091-9. (Pubitemid 34274108)
17. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011;72:849-58.
18. Chin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011;30:158-63.
19. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011;91:342-7.
20. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012;16:12-7.
21. Zeevi A, Marrari M, Feingold B, Webber S, Duquesnoy RJ. Human leukocyte antigen epitope analysis to assess complement- and non-complement-binding donor-specific antibody repertoire in a pediatric heart transplant recipient. Hum Immunol 2012;73:48-51.
22. Otten HG, Verhaar MC, Borst HP, Hene RJ, van Zuilen AD. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012;12:1618-23.
23. Lachmann N, Todorova K, Schulze H, Schonemann C. Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation 2013;95:694-700.
24. Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013;15:113-9.
25. Cristal. Agence Biomédecine (http://www.sipg.sante.fr/portail/)
26. Données Informatiques VAlidées en Transplantation (DIVAT) software (http://www.divat.fr/).
27. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003;3:708-14. (Pubitemid 36745243)
28. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;8:753-60. (Pubitemid 351347767)
29. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009;9:1099-107.
30. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donorspecific antibodies: a pilot study. Transplantation 2010;89:1403-10.
31. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450-62.
32. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004;23:2109-23. (Pubitemid 38968032)
33. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72. (Pubitemid 351193639)
34. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:Suppl 1:S1-S266.
35. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005;5:807-17. (Pubitemid 41400854)
36. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibodymediated damage despite lack of C4d staining. Am J Transplant 2009;9:2312-23.
37. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011;11:56-65.
38. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011;11:2405-13.
39. A pilot study to evaluate the use of C1 esterase inhibitor (human) in patients with acute antibody-mediated rejection. ClinicalTrials.gov (http://clinicaltrials.gov/ct2/show/NCT01147302).
40. Safety & tolerability of Berinert (C1 inhibitor) therapy to prevent rejection. ClinicalTrials.gov (http://clinicaltrials.gov/ct2/show/NCT01134510).